ArticleBreast cancer research and treatment2017
Phenotypic characterisation of breast cancer: the role of CDC42.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Spatial and planar profiling of Rac1/Cdc42 signaling in Alzheimer's disease brain.Journal of Alzheimer's disease : JAD · 2024Article
- Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis.Scientific reports · 2022Observational
- LncRNA HCP5 enhances the proliferation and migration of cervical cancer via miR-216a-5p/CDC42 axis.Journal of Cancer · 2022Article
- The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).Breast cancer research and treatment · 2021Article
- Review
- The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.Breast cancer research and treatment · 2021Article
- Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.International journal of molecular sciences · 2021Article
- Article
- Investigating potential molecular mechanisms of serum exosomal miRNAs in colorectal cancer based on bioinformatics analysis.Medicine · 2020Article
- Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.Breast cancer research and treatment · 2020Article
- Gene relevance based on multiple evidences in complex networks.Bioinformatics (Oxford, England) · 2020Article
- Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs.Cells · 2019Review
- The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42.Theranostics · 2019Article
- Downregulated expression of ARHGAP10 correlates with advanced stage and high Ki-67 index in breast cancer.PeerJ · 2019Article
- Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.Theranostics · 2019Article
- Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis.Scientific reports · 2018Article
- Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe molecular landscape of breast cancer (BC), especially of the Luminal A subtype, remains to be fully delineated. Transcriptomic data show that Luminal A tumours are enriched for aberrant expression of genes in the cell division control 42 homolog (CDC42) pathway. This study aims to investigate the protein expression of CDC42 in BC and assess its clinicopathological significance.
methodsExpression of CDC42 protein was examined by immunohistochemistry on tissue microarrays in a well-characterised cohort of 895 early-stage (I-IIIa) primary invasive BCs.
resultsCDC42 expression was observed in both the cytoplasm and the nucleus of BC cells. High nuclear CDC42 expression demonstrated a significant correlation with ER-positive, low-grade tumours and was more common in the lobular histological subtype (all p < 0.001). In contrast, cytoplasmic CDC42 showed increased expression in the ductal subtype (p < 0.001) and correlated with negative prognostic features such as larger size, higher grade (p < 0.05) and higher Ki67 labelling index (p = 0.001). Nuclear CDC42 expression was associated with a longer BC-specific survival in all cases (p = 0.025) and in luminal ER-positive tumours (p = 0.011). In multivariate analyses including size, grade, lymph node stage and intrinsic subtype, CDC42 was an independent prognostic factor (p = 0.032).
conclusionThe results indicate that CDC42 is an important molecule in luminal BC, with prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.